
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
Smart Money: Smart money is taking extra interest in the stock as they increase their holdings.
Size: Market Cap wise it is among the top 20% companies of india.
Past Returns: Outperforming stock! In past three years, the stock has provided 30.2% return compared to 9.3% by NIFTY 50.
Balance Sheet: Strong Balance Sheet.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Technicals: Bullish SharesGuru indicator.
Profitability: Recent profitability of 11% is a good sign.
Growth: Awesome revenue growth! Revenue grew 25.5% over last year and 59.7% in last three years on TTM basis.
No major cons observed.
Valuation | |
|---|---|
| Market Cap | 34.27 kCr |
| Price/Earnings (Trailing) | 43.72 |
| Price/Sales (Trailing) | 4.98 |
| EV/EBITDA | 23.95 |
| Price/Free Cashflow | -431.48 |
| MarketCap/EBT | 36.72 |
| Enterprise Value | 35.99 kCr |
Fundamentals | |
|---|---|
| Revenue (TTM) | 6.88 kCr |
| Rev. Growth (Yr) | 57% |
| Earnings (TTM) | 779.27 Cr |
| Earnings Growth (Yr) | -34.3% |
Profitability | |
|---|---|
| Operating Margin | 14% |
| EBT Margin | 14% |
| Return on Equity | 19.18% |
| Return on Assets | 10.07% |
| Free Cashflow Yield | -0.23% |
Growth & Returns | |
|---|---|
| Price Change 1W | 4.4% |
| Price Change 1M | -4.5% |
| Price Change 6M | -5.8% |
| Price Change 1Y | 0.00% |
| 3Y Cumulative Return | 30.2% |
| 5Y Cumulative Return | 31.6% |
| 7Y Cumulative Return | 34% |
| 10Y Cumulative Return | 19% |
Cash Flow & Liquidity | |
|---|---|
| Cash Flow from Investing (TTM) | -1.32 kCr |
| Cash Flow from Operations (TTM) | 990.08 Cr |
| Cash Flow from Financing (TTM) | 531.81 Cr |
| Cash & Equivalents | 413.57 Cr |
| Free Cash Flow (TTM) | -83.68 Cr |
| Free Cash Flow/Share (TTM) | -4.09 |
Balance Sheet | |
|---|---|
| Total Assets | 7.74 kCr |
| Total Liabilities | 3.68 kCr |
| Shareholder Equity | 4.06 kCr |
| Current Assets | 2.79 kCr |
| Current Liabilities | 1.25 kCr |
| Net PPE | 3.95 kCr |
| Inventory | 110.59 Cr |
| Goodwill | 120.38 Cr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.28 |
| Debt/Equity | 0.53 |
| Interest Coverage | 3.83 |
| Interest/Cashflow Ops | 7.28 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 4.5 |
| Dividend Yield | 0.24% |
| Shares Dilution (1Y) | 0.00% |
| Shares Dilution (3Y) | 0.00% |
Smart Money: Smart money is taking extra interest in the stock as they increase their holdings.
Size: Market Cap wise it is among the top 20% companies of india.
Past Returns: Outperforming stock! In past three years, the stock has provided 30.2% return compared to 9.3% by NIFTY 50.
Balance Sheet: Strong Balance Sheet.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Technicals: Bullish SharesGuru indicator.
Profitability: Recent profitability of 11% is a good sign.
Growth: Awesome revenue growth! Revenue grew 25.5% over last year and 59.7% in last three years on TTM basis.
No major cons observed.
Investor Care | |
|---|---|
| Dividend Yield | 0.24% |
| Dividend/Share (TTM) | 4.5 |
| Shares Dilution (1Y) | 0.00% |
| Earnings/Share (TTM) | 38.35 |
Financial Health | |
|---|---|
| Current Ratio | 2.24 |
| Debt/Equity | 0.53 |
Technical Indicators | |
|---|---|
| RSI (14d) | 43.89 |
| RSI (5d) | 54.74 |
| RSI (21d) | 35.61 |
| MACD Signal | Sell |
| Stochastic Oscillator Signal | Hold |
| SharesGuru Signal | Buy |
| RSI Signal | Hold |
| RSI5 Signal | Hold |
| RSI21 Signal | Hold |
| SMA 5 Signal | Buy |
| SMA 10 Signal | Buy |
| SMA 20 Signal | Sell |
| SMA 50 Signal | Sell |
| SMA 100 Signal | Sell |
Summary of Narayana Hrudayalaya's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
In the earnings call held on February 17, 2026, management of Narayana Hrudayalaya Limited provided a positive outlook for the company's future, particularly focusing on the continued growth in their India operations. Key highlights from the management's commentary include:
Profit Growth: The Indian business has shown a high profit growth for two consecutive quarters, with margin expansion of approximately 150-200 basis points Year-over-Year (YOY). Management aims to maintain these margins in the upcoming quarters.
Revenue Generation: The company is shifting towards higher value configurations, supported by transformation programs, which have led to improved revenue realizations. Increased volume in robotic cardiac surgeries is contributing positively to revenue.
Insurance Segment Breakeven: Management is optimistic about reducing losses in the insurance and clinic business segments, focusing on building awareness and customer attraction without providing a specific timeline for breakeven.
Cayman and UK Performance: The Cayman hospitals recorded revenues of $45 million, and while losses in the Cayman insurance segment widened, management is confident that efforts on underwriting performance will yield positive results in the upcoming quarters.
Capital Expenditure: Management projected a significant capital expenditure of approximately INR 3,000 crore, funded by internal accruals and debt, to support growth objectives.
Market Presence: Future expansion efforts will prioritize core markets, particularly in Bangalore and Kolkata, to consolidate their market presence and drive further revenue growth.
Overall, the management is focused on sustaining double-digit revenue growth in India, optimizing insurance offerings, and improving operational efficiencies across international markets, indicating a strategy aimed at long-term growth and profitability.
Question: "Do we expect the same trend of high profit growth in the India business to continue for a few more quarters? Are there still levers for margin expansion?" Answer: "We've implemented transformation programs and payor mix optimization initiatives over the last few years, yielding higher patient volumes and revenues. Although we don't have specific guidance, we aim to maintain our margins, barring unforeseen impacts."
Question: "When should we expect breakeven for the insurance and clinics segment?" Answer: "Currently, we're focused on building this segment and attracting customers. Breakeven timing is too early to disclose, but we aim to minimize losses and will update investors on our spending trajectory."
Question: "What distinguishes the average revenue per patient in Bangalore compared to other clusters?" Answer: "Bangalore's higher ARPP is largely due to advanced procedures like robotic surgery and transplants. While we aim to replicate this in other regions, we expect a structural difference due to varying case mixes and payor profiles."
Question: "What are the plans for the UK operations to improve profitability?" Answer: "The UK market is different, but we're focusing on applying technology and operational efficiencies from our Cayman experience. While margins may not reach Indian levels, we're targeting increased market share from private insurers, which will help."
Question: "Can we expect any timeline for cost efficiencies in the UK's doctor and employee expenses?" Answer: "We anticipate gradual improvements over the medium term as we enhance our efficiency through new technologies and processes. Focused changes will help reduce costs as a percentage of revenue."
Question: "What is your vision for NH in the next five years?" Answer: "We aim to establish a significant presence in core markets so that every community is within 25 minutes of an NH facility. We aspire to be a trusted provider while expanding our offerings across clinics, hospitals, and insurers."
Question: "What is the current status of debt and its repayment?" Answer: "We have a GBP 150 million debt with a 2+5 repayment structure. Initially, we service interest only, then commence equal principal and interest repayments over the following five years."
Question: "Are you planning to further expand your international presence?" Answer: "Currently, our focus remains on optimizing UK operations and enhancing our performance in Cayman. No immediate plans for new international acquisitions are in place."
Analysis of Narayana Hrudayalaya's financial performance, highlighting revenue trends, growth patterns, and key metrics through quarterly analysis.
Last Updated: Dec 31, 2025
| Description | Share | Value |
|---|---|---|
| Medical and healthcare related services | 93.5% | 2.1 kCr |
| Others | 5.5% | 121.6 Cr |
| Add: Unallocated other income | 1.1% | 23.3 Cr |
| Total | 2.2 kCr |
Understand Narayana Hrudayalaya ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| SHAKUNTALA SHETTY | 34.8% |
| DEVI PRASAD SHETTY | 11.66% |
| VIREN PRASAD SHETTY | 5% |
| VARUN SHETTY | 5% |
| ANESH SHETTY | 5% |
| KIRAN MAZUMDAR SHAW | 2.3% |
| MIRAE ASSET NIFTY SMALLCAP 250 MOMENTUM QUALITY 10 | 2.2% |
| NARAYANA HEALTH ACADEMY PVT LTD | 1.81% |
| FRANKLIN TEMPLETON INVESTMENT FUNDS - FRANKLIN IND | 1.27% |
| RENUKA JAGTIANI | 1.08% |
| AMEYA SHETTY | 0% |
Distribution across major stakeholders
Distribution across major institutional holders
Detailed comparison of Narayana Hrudayalaya against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| APOLLOHOSP | Apollo Hospitals Enterprises | 1.06 LCr | 24.42 kCr | -4.40% | +10.00% | 58.92 | 4.35 | - | - |
| MAXHEALTH | Max Healthcare Institute | 90.76 kCr | 8.3 kCr | -10.50% | -18.00% | 63.9 | 10.93 | - | - |
| FORTIS | Fortis Healthcare | 60.84 kCr | 8.84 kCr | -9.70% | +24.10% | 63.36 | 6.89 | - | - |
| MEDANTA | Global Health | 27.74 kCr | 4.27 kCr | -7.00% | -16.40% | 53.98 | 6.5 | - | - |
| KRISHANA | Krishana Phoschem | 3.42 kCr | 2.15 kCr | +13.80% | +136.80% | 26.37 | 1.59 | - | - |
Comprehensive comparison against sector averages
NH metrics compared to Healthcare
| Category | NH | Healthcare |
|---|---|---|
| PE | 43.72 | 57.43 |
| PS | 4.98 | 5.84 |
| Growth | 25.5 % | 12.9 % |
Narayana Hrudayalaya Limited engages in the medical and healthcare services in India and internationally. It operates through two segments, Medical and Healthcare Related Services; and Others. The company acquires, owns, and operates hospitals, clinics, health centers, diagnostic centres, nursing homes and other related activities. It offers cardiology, cardiac surgery, nephrology, urology, neurology, neuro-surgery, endocrinology, orthopedics, internal medicines, obstetrics, gynecology, pediatrics, neonatology, gastroenterology, and oncology services. The company engages in health insurance business. The company was incorporated in 2000 and is headquartered in Bengaluru, India.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
NH vs Healthcare (2021 - 2026)